Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

MiR-4649-5p acts as a tumor-suppressive microRNA in triple negative breast cancer by direct interaction with PIP5K1C, thereby potentiating growth-inhibitory effects of the AKT inhibitor capivasertib

K. Jonas, F. Prinz, M. Ferracin, K. Krajina, B. Pasculli, A. Deutsch, T. Madl, B. Rinner, O. Slaby, C. Klec, M. Pichler

. 2023 ; 25 (1) : 119. [pub] 20231006

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc24001080

BACKGROUND: Triple negative breast cancer (TNBC) is a particularly aggressive and difficult-to-treat subtype of breast cancer that requires the development of novel therapeutic strategies. To pave the way for such developments it is essential to characterize new molecular players in TNBC. MicroRNAs (miRNAs) constitute interesting candidates in this regard as they are frequently deregulated in cancer and contribute to numerous aspects of carcinogenesis. METHODS AND RESULTS: Here, we discovered that miR-4649-5p, a miRNA yet uncharacterized in breast cancer, is associated with better overall survival of TNBC patients. Ectopic upregulation of the otherwise very low endogenous expression levels of miR-4646-5p significantly decreased the growth, proliferation, and migration of TNBC cells. By performing whole transcriptome analysis and physical interaction assays, we were able to identify the phosphatidylinositol phosphate kinase PIP5K1C as a direct target of miR-4649-5p. Downregulation or pharmacologic inhibition of PIP5K1C phenocopied the growth-reducing effects of miR-4649-5p. PIP5K1C is known to play an important role in migration and cell adhesion, and we could furthermore confirm its impact on downstream PI3K/AKT signaling. Combinations of miR-4649-5p upregulation and PIP5K1C or AKT inhibition, using the pharmacologic inhibitors UNC3230 and capivasertib, respectively, showed additive growth-reducing effects in TNBC cells. CONCLUSION: In summary, miR-4649-5p exerts broad tumor-suppressive effects in TNBC and shows potential for combined therapeutic approaches targeting the PIP5K1C/PI3K/AKT signaling axis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24001080
003      
CZ-PrNML
005      
20240213093612.0
007      
ta
008      
240109s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13058-023-01716-2 $2 doi
035    __
$a (PubMed)37803350
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Jonas, Katharina $u Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria $u Research Unit for Non-Coding RNA and Genome Editing in Cancer, Medical University of Graz, Graz, Austria
245    10
$a MiR-4649-5p acts as a tumor-suppressive microRNA in triple negative breast cancer by direct interaction with PIP5K1C, thereby potentiating growth-inhibitory effects of the AKT inhibitor capivasertib / $c K. Jonas, F. Prinz, M. Ferracin, K. Krajina, B. Pasculli, A. Deutsch, T. Madl, B. Rinner, O. Slaby, C. Klec, M. Pichler
520    9_
$a BACKGROUND: Triple negative breast cancer (TNBC) is a particularly aggressive and difficult-to-treat subtype of breast cancer that requires the development of novel therapeutic strategies. To pave the way for such developments it is essential to characterize new molecular players in TNBC. MicroRNAs (miRNAs) constitute interesting candidates in this regard as they are frequently deregulated in cancer and contribute to numerous aspects of carcinogenesis. METHODS AND RESULTS: Here, we discovered that miR-4649-5p, a miRNA yet uncharacterized in breast cancer, is associated with better overall survival of TNBC patients. Ectopic upregulation of the otherwise very low endogenous expression levels of miR-4646-5p significantly decreased the growth, proliferation, and migration of TNBC cells. By performing whole transcriptome analysis and physical interaction assays, we were able to identify the phosphatidylinositol phosphate kinase PIP5K1C as a direct target of miR-4649-5p. Downregulation or pharmacologic inhibition of PIP5K1C phenocopied the growth-reducing effects of miR-4649-5p. PIP5K1C is known to play an important role in migration and cell adhesion, and we could furthermore confirm its impact on downstream PI3K/AKT signaling. Combinations of miR-4649-5p upregulation and PIP5K1C or AKT inhibition, using the pharmacologic inhibitors UNC3230 and capivasertib, respectively, showed additive growth-reducing effects in TNBC cells. CONCLUSION: In summary, miR-4649-5p exerts broad tumor-suppressive effects in TNBC and shows potential for combined therapeutic approaches targeting the PIP5K1C/PI3K/AKT signaling axis.
650    _2
$a lidé $7 D006801
650    12
$a mikro RNA $x genetika $x metabolismus $7 D035683
650    12
$a triple-negativní karcinom prsu $x farmakoterapie $x genetika $x metabolismus $7 D064726
650    _2
$a protoonkogenní proteiny c-akt $x genetika $x metabolismus $7 D051057
650    _2
$a fosfatidylinositol-3-kinasy $x metabolismus $7 D019869
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a proliferace buněk $x genetika $7 D049109
650    _2
$a pohyb buněk $x genetika $7 D002465
650    _2
$a regulace genové exprese u nádorů $7 D015972
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Prinz, Felix $u Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria $u Research Unit for Non-Coding RNA and Genome Editing in Cancer, Medical University of Graz, Graz, Austria
700    1_
$a Ferracin, Manuela $u Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
700    1_
$a Krajina, Katarina $u Translational Oncology, II. Med Clinics Hematology and Oncology, Augsburg, Germany
700    1_
$a Pasculli, Barbara $u Fondazione IRCCS Casa Sollievo della Sofferenza Laboratorio di Oncologia, San Giovanni Rotondo, FG, Italy
700    1_
$a Deutsch, Alexander $u Division of Hematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
700    1_
$a Madl, Tobias $u Division of Molecular Biology and Biochemistry, Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Medical University of Graz, Graz, Austria $u BioTechMed-Graz, Graz, Austria
700    1_
$a Rinner, Beate $u Department for Biomedical Research, Medical University of Graz, Graz, Austria
700    1_
$a Slaby, Ondrej $u Department of Biology, Faculty of Medicine and Central European Institute of Technology, Masaryk University, Brno, Czech Republic
700    1_
$a Klec, Christiane $u Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria $u Research Unit for Non-Coding RNA and Genome Editing in Cancer, Medical University of Graz, Graz, Austria
700    1_
$a Pichler, Martin $u Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria. martin.pichler@medunigraz.at $u Research Unit for Non-Coding RNA and Genome Editing in Cancer, Medical University of Graz, Graz, Austria. martin.pichler@medunigraz.at $u Translational Oncology, II. Med Clinics Hematology and Oncology, Augsburg, Germany. martin.pichler@medunigraz.at
773    0_
$w MED00006602 $t Breast cancer research $x 1465-542X $g Roč. 25, č. 1 (2023), s. 119
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37803350 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093609 $b ABA008
999    __
$a ok $b bmc $g 2049594 $s 1210774
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 25 $c 1 $d 119 $e 20231006 $i 1465-542X $m Breast cancer research $n Breast Cancer Res $x MED00006602
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Možnosti archivace